Metastatic Renal Cell Carcinoma Change Vascularity

Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Takeshi, Matayoshi, Yukihide, Sato, Yohsuke, Sato, Yujiro, Nagase, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437274/
https://www.ncbi.nlm.nih.gov/pubmed/22970402
http://dx.doi.org/10.1155/2012/654617
Descripción
Sumario:Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.

Ejemplares similares